<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: Human epidermal growth factor receptor 1 (HER1) plays an important role in the pathogenesis of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Panitumumab is an anti-HER1 monoclonal antibody approved for use in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, few data exist regarding HER1 status in the corresponding distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, and little corresponding information is available regarding the localization of panitumumab at primary and metastatic lesions </plain></SENT>
<SENT sid="3" pm="."><plain>The utility of PET and MRI using (89)Zr-panitumumab to assess the status of HER1 in distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> with different <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> models is presented in this study </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: In vivo biodistribution and PET studies were performed in HER1-expressing LS-174T and HER1-negative A375 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts </plain></SENT>
<SENT sid="5" pm="."><plain>Additionally, studies were performed in different models of intraperitoneal and <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">pulmonary metastases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>MRI studies were performed for metastatic models to characterize the targeting potential of (89)Zr-panitumumab at different lesion sites </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: HER1-mediated targeting was achieved in <z:hpo ids='HP_0000001'>all</z:hpo> HER1-expressing models </plain></SENT>
<SENT sid="8" pm="."><plain>The LS-174T <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> area under the curve (AUC) was 3.7-fold greater than the AUC for A375 </plain></SENT>
<SENT sid="9" pm="."><plain>The LS-174T <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> AUC of 204.13 ± 9.67 was significantly greater (P &lt; 0.001) than the LS-174T <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> AUC of 36.45 ± 1.39 obtained from mice coinjected with 0.1 mg of panitumumab for blocking the target </plain></SENT>
<SENT sid="10" pm="."><plain>Differences were observed in 2 intraperitoneal models; <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake in mice with a 3-d <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden was more than 2-fold greater than the mice with a 7-d <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden </plain></SENT>
<SENT sid="11" pm="."><plain>PET and MRI studies revealed HER1-mediated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> targeting in <z:hpo ids='HP_0000001'>all</z:hpo> metastatic models </plain></SENT>
<SENT sid="12" pm="."><plain>However, significant differences were observed between different LS-174T <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models </plain></SENT>
<SENT sid="13" pm="."><plain>Peak <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake of approximately 40 percentage injected dose per gram (%ID/g) was observed at 3-4 d after injection for the subcutaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> model, in contrast to approximately 75 %ID/g at 2 d after injection for the <z:e sem="disease" ids="C0039981" disease_type="Neoplastic Process" abbrv="">thoracic tumors</z:e> and approximately 95 %ID/g at 1-2 d after injection for the intraperitoneal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: The potential utility of (89)Zr-panitumumab in assessing HER1 status in distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> and understanding the variations in antibody uptake at different lesion sites is demonstrated in this study </plain></SENT>
<SENT sid="15" pm="."><plain>(89)Zr-panitumumab can play a vital role in patient stratification and immunotherapy and therefore warrants further investigation for clinical translation </plain></SENT>
</text></document>